Quality of Life in Leprosy Patient with Neuropathic Pain in Donorojo Hospital
DOI:
https://doi.org/10.66344/jpad.v31i1.1465Keywords:
Quality of Life, Leprosy, Activity Limitation, Neuropathic PainAbstract
Background Leprosy disease in the community is usually mistaken as a cursed disease. Leprosy disease is a chronic granulomatous infection caused by Mycobacterium leprae. Quality of life in leprosy patients with neuropathic pain in every region is varied.
Objective To determine the quality of life in leprosy patients with neuropathic pain by using the SALSA Scale and VAS.
Methods The research used analytic observational, a cross-sectional design and an interview technic. 37 subjects of 19 to 59 years age had leprosy with neuropathic pain at Donorojo Hospital.
Results SALSA score explains that 62.2% of the research subject has limitation of activity and has a correlation with leprosy disease with p 0.012. There is no correlation between VAS score and leprosy disease with p 0.034. SALSA score and VAS score in this research explain there is no correlation with p 0.458. The number of other medical conditions with limitation activity has a correlation score of 0.870 which has a very good correlation power. The number of used tools with limitation activity has a correlation score of 0.716 which has a good correlation power.
Conclusion There is activity limitation in leprosy patients with neuropathic pain at Donorojo Hospital Jepara District. The other aspect that affect activity limitation is the number of other medical conditions. Multibacillary type has more limitation than a Paucibacillary type.
References
1. Lee D, Rea T, Modlin R. Leprosy. In: Goldsmith LA, Kats SI, Gilchreest BA, Paller AS, Leffell DJ, Wolff K, editors. Fitzpatrick’s Dermatology in General Medicine. 8th ed. New York: McGraw-Hill; 2011. p. 6249.
2. Lockwood DNJ. Leprosy. In: Chalmers R, Barker J, Griffiths C, Bleiker T, Creamer D, editors. Rook’s Textbook of Dermatology. 9th ed. West Sussex: Wiley Blackwell; 2016. p. 4696.
3. Wisnu IM, Sjamsoe-Daili E, Menaldi SL. Kusta. In: Ilmu Penyakit Kulit dan Kelamin. 7th ed. Jakarta: Badan Penerbit FKUI; 2015. p. 544.
4. Ministry of Health of the Republic of Indonesia. Profil Kesehatan Indonesia Tahun 2017. Ministry of Health Indonesia. Jakarta; 2018. 107–8 p.
5. James WD, Berger TG, Elston DM, Neuhaus IM. Andrews’ Diseases of the Skin Clinical Dermatology. 12th ed. Philadelphia: Elsevier Ltd; 2016. 965 p.
6. Jain S. Dermatology: Illustrated Study Guide and Comprehensive Board Review. 2nd ed. Jain S, editor. Cham: Springer; 2017. 369 p.
7. Narang T, Kumar B. Leprosy in Children. Indian J Paediatr Dermatol. 2019;20:12–24.
8. Sehgal VN. Leprosy revisited. Clin Dermatol Res Ther. 2018;2(1):118.
9. Ustianowski AP, Lawn SD, Lockwood DN. Interactions between HIV infection and leprosy: a paradox. Lancet Infect Dis. 2006;6(6):350–60.
10. World Health Organization. Classification of leprosy [Internet]. [cited 2019 Mar 17]. Available from: https://www.who.int/lep/classification/en/
11. World Health Organization. Leprosy elimination [Internet]. [cited 2019 Mar 17]. Available from: https://www.who.int/lep/epidemiology/en/
12. World Health Organization. Leprosy [Internet]. [cited 2019 Mar 17]. Available from: http://apps.who.int/neglected_diseases/ntddata/leprosy/leprosy.html
13. Ministry of Health of the Republic of Indonesia. Hapuskan Stigma dan Diskriminasi Terhadap Kusta. 2018;12.
14. Eyanoer PC. Social acceptance and quality of life of leprosy patient. IOP Conf Ser Earth Environ Sci. 2018;125:1–5.
15. Slamet ES, Sukandar H, Gondodiputro S. Faktor-Faktor yang Mempengaruhi Qualiy Of Life Orang yang Pernah Mengalami Kusta di Kabupaten Cirebon. Maj Kedokt Bandung. 2014;1–19.
16. Leite IF, Arruda AJCG de, Vasconcelos DIB de, Santana SC de, Chianca KSV. The Quality of Life of Patients with Chronic Leprosy. Jounal Nurs UFPE. 2017;9(6):8165–71.
17. Joseph GA, Sundar Rao PSS. Impact of leprosy on the quality of life. Bull World Health Organ. 1999;77(6):515–7.
18. The WHOQOL Group. WHOQOL-BREF. Introduction, Administration, Scoring, and Generic Version of The Assessment. 1996;(December).
19. Santos VS, Oliveira LS, Castro FDN, Gois-Santos VT, Lemos LMD, Ribeiro M do CO, et al. Functional activity limitation and quality of life of leprosy cases in an endemic area in Northeastern Brazil. PLoS Negl Trop Dis. 2015;9(7):1–8.
20. SALSA. SALSA Scale (Screening Activity Limitation and Safety Awareness). Apeldoorn: The SALSA Collaborative Study Group; 2010. 1–33 p.
21. Videler AJ, Beelen A, Nollet F. Manual dexterity and related functional limitations in hereditary motor and sensory neuropathy. An explorative study. Disabil Rehabil. 2008;30(8):634–8.
22. Shafrin J, Sullivan J, Goldman DP, Gill TM. The association between observed mobility and quality of life in the near elderly. PLoS One [Internet]. 2017 Aug 21;12(8):e0182920–e0182920. Available from: https://www.ncbi.nlm.nih.gov/pubmed/28827806
23. Ofeibea Amedo A, Adade S, Yaa Koomson N, Appenteng Osae E. Influence of Visual Impairment on the Quality of Life: a Survey of Patients Reporting At the Low Vision Centre of the Eastern Regional Hospital of Ghana. J Ophthalmic Sci. 2016;1(3):1–13.
24. Kessing D, Denollet J, Widdershoven J, Kupper N. Self-care and health-related quality of life in chronic heart failure: A longitudinal analysis. Eur J Cardiovasc Nurs [Internet]. 2017/03/23. 2017 Oct;16(7):605–13. Available from: https://www.ncbi.nlm.nih.gov/pubmed/28895482
25. Takeda K, Sawamura S, Tamai H, Sekiyama H, Hanaoka K. Role for cyclooxygenase 2 in the development and maintenance of neuropathic pain and spinal glial activation. Anesthesiology. 2005;103(4):837–44.
26. Yamamoto D, Iwase S, Yoshida H, Kuroda Y, Yamamoto C, Kitamura K, et al. Efficacy of meloxicam in combination with preoperative chemotherapy for breast cancer - Japan Breast Cancer Research Network (JBCRN) 02-1 trial. Anticancer Res. 2011;31(10):3567–71.
27. FDA. Mobic® (Meloxicam) [Internet]. 2005. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/020938s013,015,021530s001,003lbl.pdf
28. Bjornsdottir S V, Jonsson SH, Valdimarsdottir UA. Functional limitations and physical symptoms of individuals with chronic pain. Scand J Rheumatol. 2013;42(1):59–70.
29. Elfving B, Lund I, C LB, Bostrom C. Ratings of pain and activity limitation on the visual analogue scale and global impression of change in multimodal rehabilitation of back pain - analyses at group and individual level. Disabil Rehabil. 2016;38(22):2206–16.
30. Brandsma JW, Van Brakel WH. WHO disability grading: Operational definitions. Lepr Rev. 2003;74(4):366–73.
31. Ministry of Health of the Republic of Indonesia. Temukan Kusta Sejak Dini: Tidak Ada Kecacatan, Tidak Ada Stigma [Internet]. 2017 [cited 2019 Oct 20]. Available from: http://sehatnegeriku.kemkes.go.id/baca/rilis-media/20170127/3819511/temukan-kusta-sejak-dini-tidak-ada-kecacatan-tidak-ada-stigma/
32. World Health Organization. Disabilities [Internet]. [cited 2019 Apr 10]. Available from: https://www.who.int/topics/disabilities/en/
33. Caro CC, Costa JD, Cezar da Cruz DM. The use of mobility assistive devices and the functional independence in stroke patients. Brazilian J Occup Ther. 2018;26(3):558–68.
34. Horowitz A, Brennan M, Reinhardt JP, Macmillan T. The impact of assistive device use on disability and depression among older adults with age-related vision impairments. J Gerontol B Psychol Sci Soc Sci. 2006;61(5):S274-80.
35. Parette P, Scherer M. Assistive technology use and stigma. Educ Train Dev Disabil. 2004;39(3):217–26.
36. Maia FB, Teixeira ER, Silva GV, Gomes MK. The Use of Assistive Technology to Promote Care of the Self and Social Inclusion in Patients with Sequels of Leprosy. PLoS Negl Trop Dis [Internet]. 2016 Apr 28;10(4):e0004644. Available from: https://doi.org/10.1371/journal.pntd.0004644
37. Walsh JE. The impact of assistive technology device use on the participation levels and living arrangement decisions of older adults [Internet]. Dissertation Abstracts International Section A: Humanities and Social Sciences. 2015. Available from: http://ezaccess.libraries.psu.edu/login?url=
Downloads
Published
Issue
Section
License
Copyright (c) 2021 Andy Faisal, Muslimin Muslimin, Yulian Ludovicus Aryoko Widodo S., Renni Yuniati
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
